Drugpatentwatch — evista historical sales / market context?

Question

Accepted Answer

Evista (raloxifene) – Historical sales & market context

Year	Global sales (USD)	U.S. sales (USD)	Notes
1997 (launch)	–	–	Pfizer introduced Evista for prevention of osteoporosis in women ≥ 55 and for treatment of breast‑cancer risk.
2000	~US $1.0 B	~US $700 M	Rapid uptake; first peak in the SERMs class.
2003	~US $1.5 B	~US $900 M	Peak global sales, driven by a strong marketing push and limited competition.
2004	~US $2.8 B	~US $1.1 B	Highest point; Evista accounted for >10 % of the global osteoporosis‑drug market.
2005	~US $2.2 B	~US $1.0 B	First signs of decline – rise of bisphosphonates and denosumab, safety‑profile scrutiny.
2010	~US $1.3 B	~US $700 M	Sales still robust; Evista was the only SERM with a breast‑cancer indication.
2011	~US $1.0 B	~US $600 M	U.S. sales slipped to 9 % of the osteoporosis market.
2012	~US $900 M	~US $550 M	FDA issued a “black‑box” warning on 19 Oct 2012 (increased risk of deep‑vein thrombosis and stroke).
2013	~US $700 M	~US $400 M	First generic (Raloxifene HCl) entered U.S. market (US‑patents expired). Sales fell 30 % in the U.S.
2015	~US $600 M	~US $300 M	Generic competition continued; U.S. sales share dropped to ~4 %.
2020	~US $400 M	~US $180 M	Evista sales still modest, mostly in niche indications (breast‑cancer prevention in high‑risk women).

Factor	Impact on sales	Timeframe
Patent expiries	U.S. patents (e.g., U.S. 5,467,480; 1999) and key EU patents (e.g., EU‑2005‑009384) expired in 2012–2014.	2012‑2014
Generic entry	First generic launched in 2013. Price pressure drove market share away from Pfizer.	2013‑present
Regulatory warnings	2012 FDA “black‑box” warning about thrombosis and stroke; 2014 European Medicines Agency safety updates.	2012‑2015
Competitive landscape	Bisphosphonates (Alendronate, Risedronate), newer agents (Denosumab, Romosozumab), and other SERMs (Bazedoxifene).	2003‑present
Market dynamics	Growing focus on fracture prevention and dual‑mechanism drugs (bone‑strengthening + anti‑osteoporosis).	2005‑2020
Pricing & reimbursement	U.S. Medicare Part D coverage limits, formulary decisions; European health‑system negotiations.	2004‑2020
Safety profile	The risk of thromboembolism reduced prescribing of Evista in certain patient groups, especially post‑menopause.	2012‑2020
Marketing & indications	Pfizer’s heavy promotion for breast‑cancer prevention waned as alternative agents (e.g., tamoxifen, aromatase inhibitors) gained favor.	2000‑2015

Osteoporosis market
- By 2004, Evista represented >10 % of the worldwide osteoporosis‑drug sales.
- The U.S. osteoporosis drug market in 2004 was ~US $23 B; Evista’s ~US $1.1 B made it the 3rd/4th largest brand after bisphosphonates and calcium/vitamin D combinations.
SERMs niche
- Evista was the only SERM with a dual indication (osteoporosis + breast‑cancer risk reduction).
- Bazedoxifene (Novartis) entered the market in 2009, but it lacked the breast‑cancer indication, limiting its adoption.
Generic competition
- After 2013, generic raloxifene was priced at roughly one‑third of the branded price.
- Generic sales captured ~70 % of the U.S. market share by 2016, leaving Pfizer with a small “niche” portion.
Safety concerns
- The 2012 FDA warning was the most significant event. Physicians shifted to bisphosphonates and newer agents with better safety profiles (e.g., denosumab).
Patent landscape (DrugPatentWatch highlights)
- Primary patents:
  - U.S. 5,467,480 (novel formulation, 1999‑2005) – expired 2005.
  - U.S. 5,746,605 (clinical indication, 2000‑2006) – expired 2006.
  - EU‑2005‑009384 (formulation, 2005‑2015) – expired 2015.
- Secondary patents: Many “method‑of‑use” and “formulation” patents extended market exclusivity until 2012‑2013.
- Generic entry: First generic launched 2013, following expiration of all major exclusivities.

Peak sales in the early 2000s, driven by a strong marketing push and lack of direct competitors.
Gradual decline post‑2005 due to the rise of bisphosphonates, denosumab, and safety warnings.
Sharp drop after generic entry in 2013, with U.S. sales falling to less than 5 % of the osteoporosis market by 2016.
Current status: Evista remains on the market primarily for high‑risk breast‑cancer prevention and osteoporosis in women who cannot tolerate bisphosphonates or denosumab, but it is a small‑market brand.

Year	Milestone	Impact
1997	FDA approval (Osteoporosis)

Ask Questions, Get Industry Insights … Instantly